USA

Baillie Gifford Us Growth Trust Plc

153.80
0.60 (0.39%)
Share Name Share Symbol Market Type Share ISIN Share Description
Baillie Gifford Us Growth Trust Plc LSE:USA London Ordinary Share GB00BDFGHW41 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.60 0.39% 153.80 474,548 16:35:16
Bid Price Offer Price High Price Low Price Open Price
153.60 154.00 154.00 151.60 152.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Trust,ex Ed,religious,charty -313.59 -322.91 -105.10 - 469.33
Last Trade Time Trade Type Trade Size Trade Price Currency
17:55:33 O 2,120 153.80 GBX

Baillie Gifford Us Growth (USA) Latest News (1)

Baillie Gifford Us Growth (USA) Discussions and Chat

Baillie Gifford Us Growth Forums and Chat

Date Time Title Posts
03/6/202306:23Baillie Gifford US Growth Trust156
26/3/201813:09Baillie Gifford US Growth1
26/2/201618:33test2-
26/2/201618:33test-
29/7/201309:28Trading in US Shares12

Add a New Thread

Baillie Gifford Us Growth (USA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-06-08 16:55:48153.802,1203,260.56O
2023-06-08 16:55:43153.803,1594,858.54O
2023-06-08 16:42:16152.402,8024,270.25O
2023-06-08 16:32:08153.801116.92O
2023-06-08 15:35:16153.803,9416,061.26UT

Baillie Gifford Us Growth (USA) Top Chat Posts

Top Posts
Posted at 01/6/2023 13:20 by vacendak
I guess those "growth only/no dividend" funds are at the mercy of the interest rate saga. When things calm down a bit, maybe after a short recession to dampen inflation, things should go back to normal, this time without the extravagance of yesteryear.

The PE ITs I invest in at the moment NBPE and CTPE pay a dividend, so even with the silly discount, I get something for sitting tight. Still mildly optimistic about USA but not as mad about it as I used to be. :(

Posted at 01/6/2023 13:00 by takeiteasy
Interesting views - what do you make of the pure BG USA VC fund and I won't write down the fullname in case I wrongly type it but starts with an S...it seems to have a larger discount too..
Posted at 01/6/2023 12:57 by vacendak
At least this one is with a country that should still be open for business in the future.

I got burnt badly with BGCG (China Trust) with the same remit: Pure growth/Tomorrow's companies. I exited towards the end of 2022, not so unlucky me this time as it is doing even worse now.

Still holding on USA, not crystalising my losses. I am considering adding a bit more at some point. I am currently piling into PE where the discounts are also too wide.

Posted at 21/5/2022 11:00 by vacendak
The thing about Tesla is the same as for Google.
Google is not a search engine, it is a data slurper.

Likewise, Tesla is a data slurper/AI developer that happens to sell a car on the side for collecting that data.

I am pretty sure that most of the tech companies are also not valued on what they do/sell primarily, but what they do, or will be able to do, behind the scenes. Hence the high volatility.

Anyway, USA will likely rise again.

Posted at 20/5/2022 16:41 by spectoacc
Trashed in trash.

Got eye on BG funds - SMT, USA, BGEU - but none seem like buys yet.

Epoch-defining bubble, why not an epoch-defining bust. MoneyWeek suggests we're a year away from the bottom (but who knows).

Other problems are BG's recent fondness for unlisteds - fine, when money is free and no-profit, minimal-revenue Unicorns are everywhere. Not so good when the market turns, and revaluations (down) take so long to come through. SMT's NAV clearly isn't likely to be what's currently reported, with c.30% in unlisteds.


USA Top 10 according to April Factsheet:

TSLA (still multiples over-valued)
The Trade Desk (no idea)
Space Exploration Technologies (ditto)
Stripe
Moderna
Amazon
Faire Wholesale (no idea)
Brex (no idea)
Shopify (cheaper than it was! 77% down in 6 months, 9% just today)
Illumina


BG really like Moderna, Ilumina, TSLA, seem to be in almost every fund.

Don't follow a few of those holdings - opinions welcome.

Discount getting near highs, and there's been a few buy-backs, but another big problem with BG ITs - they're sufficiently gung-ho to have gone into the tech crash with gearing, and that gearing rises the further their holdings fall.

Posted at 20/4/2022 23:40 by 29palms
Tesla reports $18.76 billion in revenue and record margins in Q1

:Tesla beat analysts’ expectations on top and bottom lines for Q1 2022
:For the period ending March 31, 2022 Tesla reported $3.22 earnings per share, and revenue of $18.76 billion
:It also recorded record automotive margins of 32.9%

:Earnings per share: $3.22 vs $2.26 expected
:Revenue: $18.76 billion vs $17.80 billion expected

Shares rose as high as 6% in after-hours trading

https://www.cnbc.com/2022/04/20/tesla-tsla-earnings-q1-2022.html

Posted at 16/11/2020 23:39 by joy division still
Well I held off...... and missed out, but in today with a decent chunk. Mind u it still looks to high, but it's the only sector I'm not in. Really not sure which of these USA ITs are best, SMT, PCT, ATT but I've probably gone for the worst future performance!
Posted at 22/7/2020 21:44 by 29palms
TSLA earnings after the bell.
Earnings: $2.18 (ex-items) vs. 3 cents per share, expected.
Revenue: $6.04 billion vs. $5.37 billion, expected.

Will provide a nice fill up to NAV

Posted at 14/7/2020 23:20 by 29palms
The good news just keeps on coming:
https://uk.advfn.com/stock-market/NASDAQ/MRNA/share-news/Modernas-Covid-19-Vaccine-Moves-to-Bigger-Study/82854797

As always,
DYOR

Posted at 18/5/2020 18:04 by whitestone
https://citywire.co.uk/funds-insider/news/the-funds-behind-the-us-stock-lifting-covid-19-vaccine-hopes/a1358349?re=74559&ea=1510734&utm_source=BulkEmail_FundsInsider+Afternoon&utm_medium=BulkEmail_FundsInsider+Afternoon&utm_campaign=BulkEmail_FundsInsider+Afternoon

The funds behind the US stock lifting Covid-19 vaccine hopes

By Daniel Grote 18 May, 2020 at 16:18

The funds behind the US stock lifting Covid-19 vaccine hopes
Baillie Gifford is among the major backers of Moderna (MRNA.O), the US biotechnology company which has sent stock markets rallying with news of a promising early trial for its experimental Covid-19 vaccine.

Shares in Moderna have surged 25% after the company reported promising results from an early study of the vaccine conducted by the US National Institutes of Health. Eight patients who were administered the vaccine were found to have antibody levels similar to those that have recovered from the coronavirus.

‘We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from Sars-CoV-2,’ said St├ęphanie Bancel, Moderna chief executive.

Global stock markets were also lifted by the news, on hopes a medical breakthrough in the fight against the coronavirus pandemic could allow locked-down economies to reopen more quickly. The FTSE 100 was up 3.3% at 5,993 while in the US, the S&P 500 opened 2.5% higher.

Growth-focused Edinburgh fund group Baillie Gifford is among the major backers of Moderna, holding just under 1% of the shares in a stake worth $284m, according to Refinitiv data. Moderna shares have soared 338% since the turn of the year on investor hopes over the progress of its coronavirus vaccine.

The fund group’s two best-performing funds of the last three years hold the stock. The £3.5bn Baillie Gifford American fund, up 117.7% over the last 36 months, has an $83.8bn stake, according to Refinitiv data accounting for around 2% of the portfolio.

The £405m Baillie Gifford Positive Change fund, the best-performing fund in the Investment Association’s Global sector over the last three years, also holds the shares. It holds a $19.4m position according to Refintiv, accounting for around 3.8% of the portfolio.

Shares in the £483m Baillie Gifford US Growth (USA) investment trust were up 3.8% at 193p today, thanks in part to its $9.4m position in Moderna shares.

BB Biotech (BION.AS) was meanwhile up 4.5% at 66.75 CHF, boosted by the £3bn Swiss investment company’s 4% portfolio stake in the stock according to the latest factsheet.

BB Biotech and Baillie Gifford were early backers of Moderna, with Baillie Gifford having invested in the stock at its flotation in December 2018. Linden Thomson, manager of the £468m AXA Framlington Biotech fund, is a more recent convert, having bought the shares in March.

‘We initiated a position in Moderna Therapeutics, which has one of the most advanced programmes to develop a vaccine against Covid-19,’ she said in her most recent update to investors. Refinitiv data shows she has built a position worth $11.9m, or around 2% of her fund.

Two exchange-traded funds have significant positions in the shares. The £102m iShares Nasdaq US Biotechnology Ucits ETF, up 2.7% today, has a 2% portfolio position according to its latest factsheet, while the $18.6m L&G Healthcare Breakthrough Ucits ETF has a 1.1% position, according to Refinitiv.

Baillie Gifford Us Growth share price data is direct from the London Stock Exchange
Your Recent History
LSE
USA
Baillie Gi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20230609 01:46:56